DR. DANIEL FADEN, MD

Plain English
This study looked at whether providing digital education about HPV and its link to a specific type of throat cancer (oropharyngeal squamous cell carcinoma) could increase the number of adults aged 18-45 willing to get HPV vaccinated. Before the education, only 32.7% were interested in the vaccine, but after the intervention, 44% ended up getting vaccinated, including a notable increase in acceptance among those who initially weren't interested (from 0% to 17.3%). This matters because HPV vaccination rates are still lower than those for other common vaccines, which could lead to more cases of HPV-related cancers. Who this helps: Patients, especially non-white adults, who are at risk for HPV-related health issues.

Plain English
This study looked at two patients with a rare type of cancer in the lacrimal sac, which is the area around the tear ducts, and both patients were positive for certain types of HPV (HPV16 and HPV33). Researchers monitored the levels of circulating tumor DNA (ctDNA) from these patients before, during, and after their treatment with chemotherapy and radiation, and found that using ctDNA tracking can effectively help detect and monitor the cancer's response to treatment. This finding is important because it supports the use of ctDNA as a non-invasive way to keep an eye on treatment success, which could guide future care for patients with this type of cancer. Who this helps: Patients with lacrimal sac squamous cell carcinoma and their doctors.

Plain English
Researchers looked at patients who had already been treated for a type of throat cancer linked to HPV to see if they developed other types of head and neck cancers that were not connected to HPV. They found that about 2.5% of patients did develop these second cancers years later, often in different areas of the mouth or throat, and many had received radiation and chemotherapy for their first cancer. This is important because it shows that these new cancers can have different causes than the original one, suggesting that doctors should monitor these patients long-term and consider retesting for HPV.

Plain English
Researchers examined a blood test that detects tumor DNA in patients with a specific type of head and neck cancer that doesn't involve HPV. They found that when the test showed positive results after treatment, it indicated a higher chance of cancer recurrence and lower survival rates. This finding is important because it suggests that this blood test could help doctors identify patients at greater risk after treatment, potentially leading to more tailored monitoring and care.

Plain English
Researchers studied a blood test that detects tiny amounts of tumor DNA in patients with a specific type of throat cancer that is not linked to HPV. They found that when this DNA was present, patients were more likely to experience a recurrence of their cancer and had a shorter survival time. This finding is important because it suggests that this blood test could help doctors predict outcomes and make better treatment decisions for patients with this type of cancer.

Plain English
Researchers developed a blood test that detects HPV cancer DNA years before oropharyngeal cancer (a common throat cancer) develops, finding the virus DNA in 79% of patient blood samples taken up to 7.8 years before diagnosis, while showing no false positives in healthy people. Using advanced computer analysis, they improved the test to detect the cancer signal in 96% of cases up to 10 years before symptoms appear. This discovery could enable doctors to catch this aggressive cancer much earlier, when treatment is more likely to succeed and causes less harm.

Plain English
This study looked at the presence of human papillomavirus (HPV) DNA in patients with anal cancer three months after they finished treatment. The researchers found that if HPV DNA was still detected at that time, patients had a higher chance of their cancer coming back; specifically, those with detectable HPV DNA faced worse outcomes. This is important because it indicates that testing for HPV DNA could help doctors identify patients who need earlier treatment to prevent recurrence. Who this helps: This helps patients with anal cancer and their healthcare providers.

Plain English
This study looked at a rare type of cancer called sinonasal squamous cell carcinoma (SNSCC), specifically how it develops and how it differs when associated with the human papillomavirus (HPV). Researchers found that HPV-related SNSCC shares certain genetic mutations found in other HPV-related cancers and identified specific mutations that are linked to worse survival rates. They also discovered that blocking certain molecular pathways could potentially improve treatment for patients with HPV-associated SNSCC. Who this helps: This helps patients with HPV-associated sinonasal squamous cell carcinoma.

Plain English
This study examined how financial difficulties, insurance issues, and transportation problems affect timely care for head and neck cancer patients in the U.S. Researchers interviewed 72 people, including 42 patients and 30 healthcare workers, and found that financial instability leads to tough choices for patients, insurance gaps create extra burdens, and transportation challenges hinder access to treatment. Addressing these issues can help make care more timely and improve experiences for patients. Who this helps: This helps patients with head and neck cancer facing financial and transportation challenges.

Plain English
This study examined how certain structures in the tumor called tertiary lymphoid structures (TLS) can help predict which patients with head and neck cancer will respond to a specific type of immunotherapy known as immune checkpoint blockade (ICB). Researchers looked at tumor samples from 20 patients, finding that those who responded to treatment had more B cells present and better survival rates when TLS were located close to the tumor. The study also showed that measuring TLS density could predict treatment response with 80% accuracy, suggesting it may be a better indicator than the currently used marker. Who this helps: This helps patients with recurrent head and neck cancer by improving treatment prediction and outcomes.

Plain English
Researchers studied how well a new test called MAESTRO could detect tiny amounts of remaining cancer after surgery in patients with head and neck cancer. They found that in a group of 24 patients, those with detectable tumor DNA in their blood immediately after surgery were more likely to experience cancer recurrence or death. Specifically, 13 out of 15 patients who had an event were found to have minimal residual disease, indicating those at higher risk for poor outcomes. This matters because detecting this residual cancer early can help doctors decide on the best follow-up treatment for patients. Who this helps: Patients with head and neck cancer undergoing surgery.

Plain English
This study looked at a new way to detect leftover cancer cells after surgery in patients with head and neck cancer. It found that among 24 patients, those with detectable levels of cancer DNA in their blood shortly after surgery were more likely to experience cancer recurrence and had worse survival rates; specifically, 92.9% of patients with recurrences had detectable cancer DNA, while only 38.5% of those without recurrences showed the same. This is important because it shows that early detection of minimal residual disease can help doctors make better treatment decisions after surgery, potentially improving patient outcomes. Who this helps: This helps patients with head and neck cancer by guiding their post-surgery treatment.

Plain English
Researchers studied 8 patients with throat cancer that had returned after initial treatment, whom doctors treated by removing the cancer with robotic surgery and then reconstructing the surgical site using a skin flap taken from under the chin. The surgery took about 5 hours on average, most patients went home within a week, and importantly, patients' ability to swallow remained normal or nearly normal even months after surgery. This approach works well because the chin flap is readily available, doesn't require specialized microsurgery skills, and produces good long-term results with low complication rates.

Plain English
Researchers studied how changes in blood samples containing tumor DNA could help predict how well patients with advanced head and neck cancer respond to treatment and how long they might live. They found that when patients had lower levels of this tumor DNA during treatment, they were more likely to respond positively and have better survival rates. This is important because using this DNA information could help doctors make better treatment decisions, potentially improving outcomes for patients.

Plain English
Researchers studied patients with a severe type of head and neck cancer that often comes back or spreads. They found that monitoring a specific marker in the blood, known as circulating tumor DNA (ctDNA), can help predict how well patients will respond to treatment and how long they might live. This is important because it offers a new way to tailor treatments to individual patients, potentially improving their chances of survival and minimizing side effects from ineffective therapies.

Plain English
Adenoid cystic carcinoma (ACC) is a deadly cancer that doesn't respond well to current treatments because tumors hide from the immune system—they have very low levels of a protein called HLA class I that the immune system needs to recognize and attack cancer cells. Researchers discovered that treating ACC tumors with immune-activating drugs called STING agonists can turn this protein back on, and when they tested this approach in one patient combined with an existing immunotherapy drug, the tumor shrank by 70%. This finding suggests that turning HLA class I back on with STING agonists could finally make immunotherapy work for ACC patients.

Plain English
Researchers developed a new blood test using advanced DNA sequencing to detect HPV-associated head and neck cancers early, before symptoms appear, and compared it to three other blood-based detection methods. The new sequencing test detected cancer 98.7% of the time it was present and correctly identified healthy people 98.7% of the time—significantly better than existing blood tests. This breakthrough matters because HPV-related head and neck cancers are becoming more common, yet doctors currently have no way to catch them early when treatment is most effective.

Plain English
Researchers developed a highly sensitive blood test that detects tiny amounts of HPV cancer DNA left in patients after surgery for HPV-related head and neck cancer. They found that patients whose blood still contained this cancer DNA had much worse outcomes—only 60% stayed cancer-free for 2 years compared to 100% of patients with no detectable DNA—and this blood test was better at predicting who would relapse than current methods doctors use. The test could also spot cancer coming back up to 17 months before it shows up on scans or causes symptoms, giving doctors an early warning system to decide whether patients need additional treatment like chemotherapy or radiation.

Plain English
This study looked at how patients' personal social networks, like family and friends, affect their ability to get care for head and neck cancer. Researchers interviewed 72 people, including 42 patients and 30 healthcare workers, and found that while social networks can provide important support, patients sometimes hesitate to ask for help or feel obligated to care for others, which can make it harder to seek medical attention. Understanding these dynamics is important because improving support from social networks can lead to earlier care and better outcomes for head and neck cancer patients. Who this helps: This helps patients with head and neck cancer and their families.

Plain English
This study looked at the presence of circulating tumor DNA (ctDNA) in patients right after surgery to see if it can predict cancer recurrence. Researchers found that in the eight studies analyzed, patients with detectable ctDNA right after surgery had a higher chance of their cancer returning, regardless of the cancer type. This is important because it suggests that checking for ctDNA soon after surgery can help doctors make better treatment decisions earlier on. Who this helps: This helps patients and doctors by providing critical information for treatment planning.

Plain English
The study looked at two tests to help diagnose HPV-related throat cancer: one that checks for HPV DNA in the blood and another that looks for antibodies against HPV proteins. Out of 75 patients, 67 had HPV-associated cancer, with 79% testing positive for antibodies and 89% for HPV DNA. Combining these tests significantly improved the chances of correctly diagnosing the cancer, making it easier for doctors to identify and treat patients early. Who this helps: This benefits patients with throat cancer and their doctors by providing more accurate diagnostic options.

Plain English
This study examined how the presence of tumor DNA in the blood predicts whether patients with early-stage throat cancer related to HPV will experience cancer recurrence or survive after surgery. The researchers found that patients who had detectable tumor DNA (MRD) after their treatment were more likely to see their cancer come back, while those without it had a better outlook. Specifically, while overall survival rates for the two groups were similar, the time until death was noticeably different, indicating that this detection method could influence long-term outcomes. Who this helps: Patients with HPV-related throat cancer and their doctors.

Plain English
This study looked at how patients with head and neck cancer get referred to specialists and the challenges they face along the way. Researchers interviewed 72 people, including 42 patients, and found that the referral process is often confusing and lacks coordination among doctors. They highlighted the importance of good communication between patients and health care providers, as well as timely referrals from primary and dental care, which can significantly improve patient outcomes. Who this helps: This helps patients with head and neck cancer by improving their chances of receiving quick and effective treatment.

Plain English
This research studied two types of sinonasal squamous cell carcinoma (SNSCC), one linked to human papillomavirus (HPV) and the other not. The study found that HPV is a key player in the development of HPV-associated tumors, and they identified specific mutations that are common in these cancers, including those in the PI3K and FGFR3 genes. Targeting certain pathways in these tumors could lead to better treatments, especially using a combination of drugs that block certain cancer-driving processes. Who this helps: This helps patients with HPV-associated sinonasal tumors.

Plain English
This study looked at the presence of human papillomavirus (HPV) in nasopharyngeal carcinoma (NPC) across different regions of the world. Researchers analyzed data from 46 studies involving over 6,300 patients, finding that the global rate of HPV-associated NPC is about 18%. North America showed the highest rate at 25%, while Asia had the lowest at 13%. Understanding HPV’s role in NPC helps improve diagnosis and treatment strategies, especially in areas where this cancer is less common. Who this helps: This information benefits doctors and patients, particularly those in non-endemic regions.

Plain English
This research study looked at how common human papillomavirus (HPV) is in nasopharyngeal carcinoma (NPC) around the world. They found that overall, 18% of NPC cases had HPV, but this varied by region, with North America showing a higher prevalence of 25%, while Asia had a lower rate of 13%. Understanding these differences is important because it highlights the role of HPV in NPC, especially in regions where it is not typically found, which can help guide future research and treatments. Who this helps: This benefits patients and doctors working with nasopharyngeal cancer.

Plain English
This research focused on different types of head and neck cancers linked to the human papillomavirus (HPV). The study identified five new groups of tumor environments that relate to how well patients are likely to do after treatment, revealing that those with the E2/E5 subtype had a much higher survival rate compared to others, suggesting that having a particular virus expression pattern can lead to better outcomes. Understanding these differences matters because it could help doctors tailor treatments based on a patient's specific cancer type. Who this helps: Patients with HPV-related head and neck cancers.

Plain English
This study looked at different methods for detecting genetic material from human papillomavirus (HPV) in the blood of patients with HPV-related cancers, specifically throat, cervical, and anal cancers. The researchers found that next-generation sequencing (NGS) was the most effective at detecting this genetic material, while digital droplet PCR (ddPCR) was also good, but less so than NGS. This matters because using the right detection method can lead to better diagnosis and treatment for patients with these cancers. Who this helps: This benefits patients with HPV-related cancers and their doctors by providing more accurate testing options.

Plain English
This study examined how the timing of immunotherapy infusions affects the survival rates of patients with head and neck cancer. The researchers found that for every 20% increase in infusions given after 3 PM, patients experienced a 35% higher risk of death and a 34% higher risk of cancer progression. This indicates that receiving immunotherapy earlier in the day could lead to better outcomes for patients. Who this helps: This helps patients with head and neck cancer and their doctors.

Plain English
This study looked at how combining a drug that stimulates the immune system (TLR8 agonist) with another drug that blocks a tumor's defenses (PD-1 blockade) works in patients with head and neck cancer. Researchers found that patients who received both treatments showed a significant increase in immune system activity, including more immune cells that attack tumors. This is important because it suggests that this combination could make cancer treatments more effective. Who this helps: Patients with head and neck cancer.

Plain English
This study looked at how certain immune cells in head and neck cancer tumors can predict whether patients will respond well to a treatment called immune checkpoint blockade (ICB). The researchers found that patients who responded to ICB had a higher amount of B lymphocytes (CD20+ cells) in their tumors compared to those who did not respond (22% vs. lower levels). Additionally, certain structures called Tertiary Lymphoid Structures (TLS) near the tumors were linked to better survival rates, with a 4% higher chance of overall survival among patients with these structures. Who this helps: This research helps patients with head and neck cancer by identifying better predictors of treatment response.

Plain English
This study looked at how two methods of cancer treatment—using a TLR8 agonist along with PD-1 blockade—work together in patients with head and neck cancer. The researchers examined tumor samples before and after treatment and found that patients who received both therapies showed significant increases in immune system activity, including more dendritic cells that help fight tumors and higher densities of cytotoxic T-cells, indicating a stronger immune response. This matters because understanding how these treatments enhance the immune response can lead to better cancer therapies. Who this helps: This research benefits cancer patients, especially those with head and neck squamous cell carcinoma.

Plain English
This study focused on detecting human papillomavirus (HPV) DNA from small amounts of blood to help identify oropharyngeal cancer caused by HPV at an early stage. The researchers found that they could accurately isolate HPV DNA from just a few milliliters of blood, achieving an 80% sensitivity rate for detecting HPV types 16 and 33. This is important because early detection can lead to better treatment options and improved quality of life for patients. Who this helps: This benefits patients at risk for HPV-related cancers by potentially allowing for earlier diagnosis and treatment.

Plain English
Researchers developed a blood test that can detect a common cancer caused by HPV (the virus linked to cervical cancer) years before symptoms appear—up to 10 years early in some cases. The test works by finding tiny pieces of HPV DNA floating in the bloodstream, which the cancer releases long before the disease becomes noticeable. When they tested blood samples taken years before patients were actually diagnosed with cancer, the test caught 79% of future cancer cases while giving zero false alarms in healthy people. Using artificial intelligence to analyze the blood samples improved detection even further, catching 96% of cases. This matters because unlike cervical cancer, there's currently no screening test for this type of HPV-related throat cancer—the most common HPV cancer in America. A blood test that finds it a decade early could save lives by catching cancer when it's easiest to treat.

Plain English
This study looked at the knowledge and opinions about human papillomavirus (HPV) and its vaccine among adults aged 18 to 45 who visited a clinic. Researchers found that only 26.6% of surveyed patients were vaccinated, and less than a quarter knew that HPV can lead to throat cancer (OPSCC). Raising awareness about this connection and offering vaccinations during clinic visits could significantly increase vaccination rates and help prevent future cancer cases. Who this helps: This benefits patients, particularly young adults who are vulnerable to HPV-related cancers.

Plain English
This study looked at how circulating tumor DNA (ctDNA) levels right after surgery can indicate the risk of cancer coming back. Researchers found that in patients with six types of cancer, those who tested positive for ctDNA within three days post-surgery were at a higher risk of recurrence. This matters because it shows that checking ctDNA soon after surgery can help guide future treatment decisions. Who this helps: Patients recovering from cancer surgery.

Plain English
This study looked at what factors affect the levels of a specific type of cancer DNA (ctHPV16) in the blood of patients with HPV-related throat cancer when they are first diagnosed. Researchers found that pain levels, tumor volume, certain blood markers like CYFRA 21-1 and C-reactive protein, as well as lymph node status, significantly influenced the ctHPV16 levels. This information is important because it can help doctors better understand the severity of the cancer at diagnosis and tailor treatment accordingly. Who this helps: Patients with HPV-related throat cancer and their doctors.

Plain English
Researchers studied 131 patients with HPV-positive throat cancer who had surgery to remove lymph nodes from their necks, looking at where the cancer had spread. They found that unusual spread patterns—where cancer appears in lower neck levels while skipping the upper levels—happened in only 5% of patients. These results suggest surgeons may be able to safely skip removing lymph nodes from the lowest neck level in some HPV-positive throat cancer patients, potentially reducing surgery complications without compromising cancer treatment.

Plain English
Surgeons sometimes rebuild the head and neck after cancer or injury by taking tissue from the arm or chest and grafting it to the damaged area. This study compared how well patients' arms and shoulders work after four different types of these grafts, measuring disability using a standard questionnaire given an average of 20 months after surgery. All four graft types resulted in similar outcomes: patients reported minimal to mild arm problems and generally functioned well, meaning the choice of graft type doesn't significantly affect how much your arm gets worse after surgery.

Plain English
Researchers tracked blood tests that measure HPV DNA in two throat cancer patients to monitor their disease during and after treatment. Both patients unexpectedly developed a second separate HPV-related cancer while being treated for their first one, which made the blood test results confusing because the test couldn't tell which cancer the detected DNA was coming from. This matters because as doctors increasingly use this blood test to catch cancer recurrence early, they need to know that rising levels don't always mean the original cancer is coming back—a patient might have developed a completely new cancer instead, which requires different treatment decisions.

Plain English
This study looked at a rare type of cancer called adenoid cystic carcinoma (ACC), which affects the salivary glands. Researchers reviewed 55 studies and found that a specific genetic change, known as MYB-NFIB translocation, is a key driver of this cancer. They also noted other targets like cKIT, the EGFR pathway, and NOTCH1, but these have shown limited success in treatments. Understanding these molecular details is important for developing better therapies. Who this helps: This helps patients with adenoid cystic carcinoma and their doctors looking for more effective treatment options.

Plain English
This study looked at whether a specific type of HPV DNA (known as circulating tumor HPV DNA) could be found in the blood of people before they were diagnosed with HPV-related head and neck cancer. Among 12 patients studied, 30% had detectable HPV DNA in their blood up to 43 months before their cancer diagnosis, while none of the 100 healthy individuals showed this DNA. Finding this DNA early could lead to earlier diagnosis and potentially better treatment outcomes for these patients. Who this helps: This helps patients at risk for HPV-related head and neck cancer.

Plain English
This study looked at how specific genetic changes in the human papillomavirus type 16 (HPV16) affect survival rates for patients with oropharyngeal cancer (a type of throat cancer). Researchers analyzed 460 tumor samples and found that certain genetic variations (called SNPs) in HPV16 are linked to poorer survival. For instance, patients with high-risk SNPs had a median survival of about 4 years, while those without these SNPs had a median survival of nearly 19 years. This finding helps doctors better predict which patients might have a worse outcome and tailor their treatments accordingly. Who this helps: Patients with oropharyngeal cancer.

Plain English
This study looked at a type of throat and neck cancer called Head and Neck Squamous Cell Carcinoma (HNSCC), which doesn't respond well to certain immune therapies. Researchers examined a patient's cancer cells and found that a specific gene change might explain why the treatment failed in one tumor, while the others responded well. Additionally, they discovered that one of the tumors was actually a spread (metastasis) from the original cancer, not a new tumor. Who this helps: This helps patients with HNSCC and their doctors understand treatment responses better.